Guizhou Tiandi Pharmaceutical Co., Ltd.

Company Profile

COMPANY INFORMATION

Guizhou Tiandi Pharmaceutical Co., Ltd. is a green, environmentally friendly, automated, and highly intelligent injection production enterprise, established in August 1995, located in the Hongxing Pharmaceutical Industry Park of Yilong High-tech Zone, Qianxinan Prefecture. It has wholly-owned subsidiaries including Guizhou Tiandi Pharmaceutical Import and Export Co., Ltd., Guizhou Guande Real Estate Development Co., Ltd., and Guizhou Tiandi Pharmaceutical Packaging Materials Co., Ltd.

There are more than 600 existing employees, 4 large-volume injection production lines with 24 varieties of injectables, and 6 small-volume injection production lines with 17 varieties of injectables. The annual production capacity of large-volume injectables is 360 million bottles, while the annual production capacity of small-volume injectables is 1 billion units. The products are mainly sold to 18 provinces (regions) including Guizhou, Yunnan, Guangxi, and Guangdong, and are exported and commissioned for processing to some countries and regions in South America, Africa, and Asia.

Since entering the Hongxing Pharmaceutical Industry Park in Yilong High-tech Zone in November 2018, Guizhou Tiandi Pharmaceutical's production capacity has been released year by year, with sales revenue and tax contributions increasing annually.In a market environment with severe 'involution,' compared to the same period in 2023, the domestic sales volume of Guizhou Tiandi Pharmaceutical has declined somewhat in 2024, while the volume of foreign trade orders has increased significantly, with the annual sales revenue including tax reaching nearly 320 million yuan, a slight increase compared to 2023, and the total tax contributions for the year amounting to nearly 16 million yuan.

With the increase in foreign trade business volume, the foreign trade business level of Guizhou Tiandi Pharmaceutical is becoming increasingly mature. In 2024, it obtained its first international pharmaceutical production quality certification: the Ethiopia EFDA certificate; it has registered nearly 50 products in more than ten countries including Nigeria, Peru, and Uzbekistan, laying a solid foundation for entering the international market. In 2025, Guizhou Tiandi Pharmaceutical will continue to seize the good opportunity of the province and state to vigorously develop industries, strengthen manufacturing, and promote economic and social development, striving to achieve an annual production and sales target of 100 million large-volume injections, 1.15 billion small-volume injections, and sales revenue of approximately 350 million yuan.

In the next five years, Guizhou Tiandi Pharmaceutical will continue to strengthen internal management, continuously improve management levels, constantly adjust product structure, and actively expand market channels. First, we will organize production in accordance with the law and regulations to meet the basic clinical medication needs in the domestic market; second, we will vigorously expand the international market: continue to carry out product registration and international quality certification for production in various regions globally, and further expand the legal channels for entering the international market, allowing the company's products to better and more extensively reach the international market.By fully seizing the strategic opportunity of the national implementation of the 'Belt and Road' initiative, we will expand export scale, enhance corporate competitiveness, and promote the company to achieve high-quality development, striving to make Guizhou Tiandi Pharmaceutical a major domestic producer of essential medicines and a key production base for international injectable drug exports, contributing more to local economic and social development.

END

Pictures and text| Li Wanlin

typesetting| Li Wanlin

Initial review| Lei Shimi

Final review| Liu Zhengchao

Guizhou Tiandi Pharmaceutical Recruitment Notice

分享至微信分享